Ontology highlight
ABSTRACT:
SUBMITTER: Muz B
PROVIDER: S-EPMC4714737 | biostudies-literature | 2016
REPOSITORIES: biostudies-literature
Muz Barbara B Ghazarian Rachel Nicole RN Ou Monica M Luderer Micah John MJ Kusdono Hubert Daniel HD Azab Abdel Kareem AK
Drug design, development and therapy 20160111
Despite the significant therapeutic advances achieved with proteasome inhibitors (PIs) such as bortezomib and carfilzomib in prolonging the survival of patients with multiple myeloma, the development of drug resistance, peripheral neuropathy, and pharmacokinetic limitations continue to pose major challenges when using these compounds. Ixazomib is a second-generation PI with improved activity over other PIs. Unlike bortezomib and carfilzomib, which are administered by injection, ixazomib is the f ...[more]